Abhd5 and partial hdac4 fragments and variants as a therapeutic approach for the treatment of cardiovascular diseases
AssigneeRuprecht-Karls-UniversitäT Heidelberg
InventorsJohannes Backs, Zegeye Jebessa, Lorenz Lehmann, Hugo Katus, Oliver Müller
Life of this patent
Estimating the term…
Abstract
The present invention relates to Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT) and variants of the aforementioned peptides for the treatment and prevention of heart failure. The present invention further provides vectors for the cardiomyocyte-specific expression of said peptides and a test system comprising ABHD5 for the identification of novel compounds which are useful for the treatment of heart failure.
Claims20
1-17. (canceled)
An abhydrolase containing domain 5 (ABHDS) or variant thereof or a vector comprising a nucleic acid encoding said ABHDS or variant thereof.
An elongated and/or multimerized variant of the N-terminal fragment of histone deacetylase 4 (HDAC4-NT) or a vector comprising a nucleic acid encoding said HDAC4-NT variant.
A method of treating or preventing heart failure comprising administering an effective amount of ABHD5 or a variant thereof or a vector comprising a nucleic acid encoding said ABHD5 or a variant thereof or HDAC4-NT or a variant thereof or a vector comprising a nucleic acid encoding HDAC4-NT or a variant thereof to a patient.
A pharmaceutical composition comprising ABHD5 or a variant thereof or a vector comprising a nucleic acid encoding said ABHD5 or a variant thereof or HDAC4-NT or a variant thereof or a vector comprising a nucleic acid encoding HDAC4-NT or a variant thereof.
A method for identifying a compound which modulates the activity and/or localization of ABHD5 or a variant thereof comprising the steps of:
- a) contacting a test system comprising ABHD5 or a variant thereof with a candidate compound;
- b) determining whether the candidate compound modulates the activity and/or localization of ABHD5 or the variant thereof;
- and
- c) identifying the compound as a compound which modulating the activity and/or localization of ABHD5 based on the comparison of the activity of ABHD5 or the variant thereof in the test system comprising the candidate compound and the activity of ABHD or the variant thereof determined in a control in step b).
Dependencies are inferred from the claim text.